Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

PaedsSeq Nanopore sequencing of cell-free DNA for the sensitive detection, molecular profiling and monitoring of childhood cancers

Coordinator
European Molecular Biology Laboratory, Germany
Runs
1 June 2023 to 31 May 2025
Status
Running
EU funding
€221k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101106070

What the project is doing

In the project's own words, from its summary on CORDIS.

Paediatric cancer is the leading cause of death in children post infancy in the Western world. The integration of high-throughput molecular profiling is now urgently needed to guide clinical decision-making and treatment stratification. However, access to adequate tumour material for genomic profiling remains highly challenging, particularly in children with refractory cancers, due to sampling difficulties and small sample volumes.

The analysis of cell-free DNA (cfDNA) from liquid biopsies for the detection of circulating tumour DNA (ctDNA) could offer a powerful, minimally invasive alternative to tumour profiling, thus circumventing sampling limitations. However, current ctDNA approaches have limited specificity and sensitivity, and their clinical implementation is hindered by poor scalability and high costs associated with conventional sequencing technologies.

In contrast, emerging nanopore sequencing platforms have faster turnaround times, are more affordable and significantly smaller than conventional sequencers, making them easy to deploy and implement in healthcare settings. However, their utility for cfDNA analyses remains largely unexplored. Here, using available data and liquid biopsy samples from ~500 children with cancer, I will develop computational tools for the detailed analysis of cfDNA nanopore sequencing data.

By harnessing nanopores ability to sequence native DNA, thus allowing the detection of mutational DNA alterations and epigenetic modifications from the same assay, I will: (a) establish highly sensitive and specific approaches for the detection and molecular profiling of ctDNA, (b) develop methylation-based disease classifiers for accurate diagnosis and treatment stratification, and (c) evaluate the clinical utility of cfDNA nanopore sequencing to monitor treatment response and detect cancer relapse.

The clinical implementation of these approaches could therefore significantly improve disease management and outcomes for children with cancer.

Topics

Who is involved

OrganisationCityCountryRole
European Molecular Biology LaboratoryHeidelbergGermanyCoordinator
The University of BirminghamBirminghamUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI